Exact Sciences said a major study on its second product in the pipeline — a test for lung cancer — will likely begin in early 2018.
B. Lynn Allen-Hoffman and Stratatech are full of big ideas at University Research Park.
Invenra today announced a collaboration with Merck, known as MSD outside the United States and Canada, to discover fully human therapeutic antibodies against an unnamed target of interest to Merck.
In Madison, Wisconsin the tech job market grew 5% in 2013-2014 and a whopping 30% in 2015-2016, making it the market with the most momentum.
A regenerative medicine treatment for skin burns developed by Stratatech could make it to the market more quickly following a regulatory decision announced Tuesday.
Varigen Biosciences, based at URP, received the Qualified New Business Venture certification, which allows investors in qualified startup and early-stage companies to receive a 25 percent state tax credit on the amount they invest in the business.
Stratatech, a University of Wisconsin–Madison spinoff, located at URP, that makes an innovative material designed to speed healing of serious burns has begun a large clinical trial for the “regenerative skin tissue” it has been developing since 2000.
Exact Sciences Corp.’s fortunes are on the upswing. Sales of its Cologuard test for colorectal cancer are on the rise, its stock is hitting record highs, and the company has padded its coffers with the sale of even more stock. Its new research and development center is fully occupied, and Exact is looking for more […]
Watch a video that highlights Exact Sciences’ innovative research and development in cancer detection.
Illumina has received US Food and Drug Administration approval for a companion diagnostic test, which it has been developing with Amgen, to run on its MiSeqDx system.